LONDON--(BUSINESS WIRE)--The global neuroendocrine tumors therapeutics market is poised to grow by USD 1.83 billion during 2019-2023, progressing at a CAGR of almost 9% during the forecast period. Request free sample pages
Read the 120-page report with TOC on “Neuroendocrine Tumors Therapeutics Market Analysis Report by Type (Somatostatin analogs, Targeted therapies, and Other therapies), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2019-2023”.
The market is driven by increasing research grants and funding. In addition, rising awareness and strategic alliances will boost the growth of the neuroendocrine tumors therapeutics market.
Many government and non-government organizations across the world are providing funds and grants as well as clinical assistance for the treatment of various neuroendocrine tumors. They are also increasing the awareness about the condition to boost the interest of developing novel treatment options. For instance, in 2017, the Neuroendocrine Tumor Research Foundation (NETRF) announced to fund USD 4 million in collaborative grants for neuroendocrine tumor research. Such initiatives are attracting vendors and resulting in better and quicker development of therapies for the treatment of neuroendocrine tumors. This will strengthen the drug development pipeline of neuroendocrine tumors and drive the growth of the market.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Neuroendocrine Tumors Therapeutics Market Companies:
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd operates the business under two segments, namely pharmaceuticals and diagnostics. XELODA is the key offering of the company. It is also known as capecitabine tablets. It is available in two strengths, 150 mg and 500 mg.
Ipsen Pharma operates the business under two segments such as specialty care and consumer healthcare. SOMATULINE DEPOT is the key offering of the company. It is a lanreotide injection, which is available in three strengths: 60 mg, 90 mg, and 120 mg.
Merck & Co., Inc
Merck & Co., Inc operates the business across various segments such as pharmaceutical, animal health, and other. TEMODAR is the key offering of the company. It is available as capsules in 5 mg, 20 mg, 100 mg, and 250 mg doses.
Novartis AG operates the business through various segments such as innovative medicines, Sandoz, and Alcon. AFINITOR, LUTATHERA, and Sandostatin LAR Depot are some of the key offerings of the company.
Pfizer Inc. operates the business across two segments such as innovative Health and essential Health. Some of the key products offered by the company include BAVENCIO and SUTENT.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Neuroendocrine Tumors Therapeutics Type Outlook (Revenue, USD Billion, 2019 - 2023)
- Somatostatin analogs
- Targeted therapies
- Other therapies
Neuroendocrine Tumors Therapeutics Regional Outlook (Revenue, USD Billion, 2019 - 2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Healthcare include:
Global Gastrointestinal Stromal Tumors Therapeutics Market – Global gastrointestinal stromal tumors therapeutics market by RoA (oral and parenteral) and geography (Asia, Europe, North America, and ROW).
Global Brain Tumor Therapeutics Market – Global brain tumor therapeutics market by type (small molecules and biologics) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org